Does Quartz Health Solutions Cover Wegovy?
The verdict
Conditional on most plans
Quartz Health Solutions covers Wegovy for weight loss only where the employer purchased the anti-obesity benefit; weight-loss coverage is excluded where the employer did not opt in. Quartz is a provider-owned Wisconsin and Upper-Midwest plan, and its drug-level Wegovy formulary detail is not publicly published — members must verify coverage through the plan's drug-lookup tool or member services.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Quartz Health Solutions using your member ID.
Key facts
Quartz Health Solutions is a provider-owned plan serving Wisconsin and the Upper Midwest; its Wegovy weight-loss coverage is employer-dependent and not published at the drug level.
Quartz Health Solutions member resources
Wegovy's list price is $1,349/month; Novo Nordisk announced a reduction to approximately $675/month effective January 1, 2027.
Novo Nordisk press release, 2026
The Medicare GLP-1 Bridge launches July 1, 2026, giving eligible Medicare beneficiaries Wegovy weight-loss access at $50/month outside Part D — not counting toward the $2,100 OOP cap.
CMS.gov, Medicare GLP-1 Weight Loss Drug Access Program
Medicare vs. commercial coverage
Whether Quartz Health Solutions covers Wegovy depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare Part D cannot cover Wegovy for weight loss by statute — this applies to all Quartz Medicare plans. Quartz Medicare plans can cover Wegovy for the cardiovascular risk-reduction indication (FDA-approved for adults with established CVD who are overweight or obese) with prior authorization. The Medicare GLP-1 Bridge launches July 1, 2026, giving eligible Medicare beneficiaries weight-loss access to Wegovy at $50/month through December 31, 2027 — this operates outside Part D, so the $50 does not count toward the $2,100 OOP cap or TrOOP. Extra Help cannot be applied to Bridge copays. NovoCare savings card is not available to Medicare beneficiaries.
Commercial / Employer
Group & marketplace plans
Quartz commercial and employer plans cover Wegovy for weight loss only when the employer has purchased the anti-obesity benefit. Where the benefit is included, prior authorization is required: typically BMI 30 or higher, or BMI 27 or higher with a weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea), plus documented participation in a lifestyle or weight-management program and demonstrated weight loss for renewal. Where the employer did not opt in, weight-loss Wegovy is excluded — this is a benefit design decision, not a medical-necessity denial. ACA/individual-market Quartz plans generally exclude Wegovy for weight loss. Wisconsin Medicaid GLP-1 obesity coverage is state-dependent; verify on the Quartz formulary or WI Medicaid PDL. Commercially insured Quartz members whose plan covers Wegovy may use the NovoCare savings card at $25/month (max $100 per 28-day supply; not available to Medicare or Medicaid).
The 4 boxes you must tick to get approved
Commercial plans that will consider Wegovy require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 4 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Wegovy actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
$1,349/month (Novo Nordisk published list price for a 28-day supply). NovoCare self-pay: approximately $349/month for standard injection doses after an introductory period through December 31, 2026.
List price with no coverage — before any manufacturer savings card.
With coverage
Plan-specific cost-share where covered — not publicly published at the drug level. Confirm your specific cost-share on Quartz's drug-lookup tool or member portal. NovoCare savings card: commercially insured Quartz members whose plan covers Wegovy may pay as little as $25/month (max $100 per 28-day supply). Not available to Medicare or Medicaid beneficiaries.
Typical monthly copay once prior authorization is approved.
Bridge program
Medicare GLP-1 Bridge: $50/month fixed copay for eligible Medicare beneficiaries, launching July 1, 2026, through December 31, 2027. Operates outside Part D — does not count toward the $2,100 OOP cap, TrOOP, or Extra Help. Provider must attest eligibility at initiation.
Reduced copay through the assistance program, where eligible.
All cost figures are estimates. Actual cost-share varies by plan tier, deductible phase, and pharmacy — confirm with your Quartz plan and pharmacist before starting treatment.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Ask HR whether your employer included the anti-obesity benefit
Before searching formularies, confirm with your HR benefits team whether anti-obesity medications are in your plan. If the employer did not purchase the benefit, no formulary search or PA submission will change that — it is a benefit exclusion, not a medical-necessity question.
- 2
Search Quartz's drug-lookup tool for your specific plan
Go to quartzbenefits.com and use the formulary or drug-lookup tool with your member ID. Search for 'Wegovy' or 'semaglutide 2.4 mg' to confirm tier, prior-authorization requirements, and quantity limits for your actual plan.
- 3
Work with your prescriber on prior authorization
If your plan covers Wegovy, your doctor will submit a PA to Quartz. Gather documentation: BMI measurement, relevant comorbidities, and evidence of lifestyle program participation. Track your weight-loss progress before each renewal to ensure you meet the reauthorization threshold.
Options if Quartz Health Solutions won't cover Wegovy
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Ozempic (semaglutide for T2D)
If you have type 2 diabetes, Ozempic (semaglutide) is broadly covered for T2D with PA across most plans regardless of whether the employer opted into anti-obesity coverage. Ozempic is not FDA-approved for weight loss and should not be prescribed for that indication.
NovoCare self-pay program
Novo Nordisk's NovoCare Pharmacy offers Wegovy at approximately $349/month for patients without coverage. An introductory rate of approximately $199/month applies to the 0.25 and 0.5 mg doses through December 31, 2026. List price is announced to drop to approximately $675/month effective January 1, 2027.
Compounded semaglutide
Compounded semaglutide is available without insurance for patients who cannot access covered Wegovy. See the Curex offer below. Compounded medications are not the same as Wegovy and have not been approved by the FDA.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
Quartz covers Wegovy for weight loss only on employer plans where the anti-obesity benefit was purchased. If your employer did not opt in, Wegovy weight-loss coverage is excluded — no PA will override a benefit design decision. Quartz does not publish drug-level Wegovy detail publicly, so the only way to confirm coverage is through the plan's drug-lookup tool at quartzbenefits.com or by calling member services. ACA/individual plans generally exclude weight-loss GLP-1s.
Quartz Health Solutions and Network Health are both Wisconsin regional plans with not-publicly-published Wegovy formulary detail, and both gate weight-loss coverage on employer opt-in. The key distinction is structure: Quartz is a provider-owned cooperative plan, while Network Health is a commercial insurer with a notable Medicare Advantage book. For commercial weight-loss seekers, the decision variable is identical — employer benefit design — but members should verify on their specific plan's drug-lookup tool rather than assuming the plans behave identically.
Where the anti-obesity benefit is included, Quartz requires prior authorization with BMI 30 or higher (or 27 with a weight-related comorbidity such as hypertension, T2D, dyslipidemia, or sleep apnea), documented lifestyle program participation, and demonstrated weight-loss progress for renewal. Specific Quartz PA criteria are not publicly published at the drug level — confirm current requirements with Quartz member services or your prescriber before submitting.
No. Medicare Part D cannot cover Wegovy for weight loss by statute — this is a federal rule applying to all plans including Quartz. Quartz Medicare plans can cover Wegovy for the cardiovascular risk-reduction indication in members with established CVD. The Medicare GLP-1 Bridge (launching July 1, 2026) provides weight-loss access at $50/month outside Part D for eligible beneficiaries — verify Bridge eligibility with your prescriber.
Commercially insured Quartz members whose plan covers Wegovy may use the NovoCare savings card to pay as little as $25/month (up to $100 savings per 28-day supply). The card is not available to Medicare or Medicaid beneficiaries. If your Quartz employer plan includes the anti-obesity benefit and covers Wegovy, the NovoCare card is a legitimate way to reduce your cost-share.
Related Articles
Does Quartz Health Solutions Cover Mounjaro? 2026 | Curex
Quartz Health Solutions (WI) covers Mounjaro for type 2 diabetes with prior auth — not weight loss. Composite plan; verify on Quartz formulary.
Read moreDoes Quartz Health Solutions Cover Ozempic? 2026 | Curex
Quartz Health Solutions covers Ozempic for type 2 diabetes with prior auth — not weight loss. Wisconsin regional plan; verify tier on Quartz member portal.
Read moreDoes Geisinger Health Plan Cover Wegovy? 2026 | Curex
Geisinger Wegovy coverage is employer-dependent and unpublished. PA Medicaid dropped GLP-1 obesity coverage in 2026. How to verify.
Read moreDoes Group Health Cooperative Cover Wegovy? 2026 | Curex
Group Health Cooperative covers Wegovy only where your employer opted in. Wisconsin co-op — drug-level detail not public. Verify on GHC's drug-lookup tool.
Read moreDoes Security Health Plan Cover Wegovy? 2026 | Curex
Security Health Plan (Marshfield Clinic) covers Wegovy only where your employer opted in. Not publicly published — verify on the plan's drug-lookup tool.
Read moreDoes UPMC Health Plan Cover Wegovy? PA Plans 2026 | Curex
UPMC covers Wegovy for weight loss only where employers opted in. PA Medicaid dropped GLP-1 obesity coverage January 2026. Verify on UPMC drug lookup.
Read moreWhether or not Quartz Health Solutions covers Wegovy, there's a path that skips insurance
Quartz covers Wegovy for weight loss only where the employer opted in. For patients without that benefit, Curex offers compounded semaglutide from $49/mo (compounded tirzepatide from $149/mo) at getcurex.com/cl/glp — no insurance, no prior authorization. Compounded semaglutide is not the same medication as Wegovy. Prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Wegovy and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Quartz Health Solutions before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Wegovy and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.